Safety, immunogenicity and effect on viral rebound of HTI vaccines in early treated HIV-1 infection: a randomized, placebo-controlled phase 1 trial.
Journal article
Bailón L. et al, (2022), Nature medicine
Specific human cytomegalovirus signature detected in NK cell metabolic changes post vaccination.
Journal article
Woods E. et al, (2021), NPJ vaccines, 6
Effect of epitope variant co-delivery on the depth of CD8 T cell responses induced by HIV-1 conserved mosaic vaccines
Journal article
Wee EG. et al, (2021), Molecular Therapy - Methods & Clinical Development, 21, 741 - 753
Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial.
Journal article
Fidler S. et al, (2020), Lancet (London, England), 395, 888 - 898
Novel Nested Peptide Epitopes Recognized by CD4+ T Cells Induced by HIV-1 Conserved-Region Vaccines.
Journal article
Borthwick N. et al, (2020), Vaccines, 8
Corrigendum to 'Therapeutic vaccination refocuses T-cell responses towards conserved regions of HIV-1 in early treated individuals (BCN 01 study)' EClinicalMedicine 11 (2019) 65-80.
Journal article
Mothe B. et al, (2020), EClinicalMedicine, 18
HIVconsv Vaccines and Romidepsin in Early-Treated HIV-1-Infected Individuals: Safety, Immunogenicity and Effect on the Viral Reservoir (Study BCN02).
Journal article
Mothe B. et al, (2020), Frontiers in Immunology, 11
In vivo Effects of Romidepsin on T-Cell Activation, Apoptosis and Function in the BCN02 HIV-1 Kick&Kill Clinical Trial.
Journal article
Rosás-Umbert M. et al, (2020), Frontiers in immunology, 11
Aiming for protective T-cell responses: a focus on the first generation conserved-region HIVconsv vaccines in preventive and therapeutic clinical trials
Journal article
Hanke T., (2019), Expert Review of Vaccines, 1 - 13
Parallel Induction of CH505 B Cell Ontogeny-Guided Neutralizing Antibodies and tHIVconsvX Conserved Mosaic-Specific T Cells against HIV-1.
Journal article
Wee EG. et al, (2019), Mol Ther Methods Clin Dev, 14, 148 - 160
Recombinant BCG Expressing HTI Prime and Recombinant ChAdOx1 Boost Is Safe and Elicits HIV-1-Specific T-Cell Responses in BALB/c Mice.
Journal article
Kilpeläinen A. et al, (2019), Vaccines (Basel), 7
MTBVAC-Based TB-HIV Vaccine Is Safe, Elicits HIV-T Cell Responses, and Protects against Mycobacterium tuberculosis in Mice
Journal article
Broset E. et al, (2019), Molecular Therapy - Methods and Clinical Development, 13, 253 - 264
Therapeutic Vaccination Refocuses T-cell Responses Towards Conserved Regions of HIV-1 in Early Treated Individuals (BCN 01 study).
Journal article
Mothe B. et al, (2019), EClinicalMedicine, 11, 65 - 80
Efficient Induction of T Cells against Conserved HIV-1 Regions by Mosaic Vaccines Delivered as Self-Amplifying mRNA
Journal article
Moyo N. et al, (2019), Molecular Therapy - Methods and Clinical Development, 12, 32 - 46
Effective Suppression of HIV-1 Replication by Cytotoxic T Lymphocytes Specific for Pol Epitopes in Conserved Mosaic Vaccine Immunogens.
Journal article
Zou C. et al, (2019), J Virol
Identification of novel HIV-1-derived HLA-E-binding peptides.
Journal article
Hannoun Z. et al, (2018), Immunol Lett
CD8+ T cells specific for conserved, cross-reactive Gag epitopes with strong ability to suppress HIV-1 replication.
Journal article
Murakoshi H. et al, (2018), Retrovirology, 15
A Novel Vaccine Strategy Employing Serologically Different Chimpanzee Adenoviral Vectors for the Prevention of HIV-1 and HCV Coinfection.
Journal article
Hartnell F. et al, (2018), Frontiers in immunology, 9
Randomized phase I trial HIV-CORE 003: Depletion of serum amyloid P component and immunogenicity of DNA vaccination against HIV-1.
Journal article
Borthwick NJ. et al, (2018), PLoS One, 13
Randomized phase I trial HIV-CORE 003: Depletion of serum amyloid P component and immunogenicity of DNA vaccination against HIV-1.
Journal article
Borthwick NJ. et al, (2018), PLoS One, 13